Spyre Therapeutics expects $486.2M cash as of Sept 30, 2025

Spyre Therapeutics, Inc.

Preliminary unaudited cash, cash equivalents and marketable securities of ~$486.2M as of Sept 30, 2025.
Full Q3 2025 financial results not yet finalized; subject to completion of closing procedures.
Company cautions that final amount may differ materially from preliminary estimate.

item 2.02

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-237904

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.